key: cord-0823847-jps0wjls
authors: Singh, Yogendra; Gupta, Gaurav; Satija, Saurabh; Pabreja, Kavita; Chellappan, Dinesh Kumar; Dua, Kamal
title: COVID‐19 transmission through host cell directed network of GPCR
date: 2020-04-23
journal: Drug Dev Res
DOI: 10.1002/ddr.21674
sha: bc058587685aee826812f87834cba840b5ff2082
doc_id: 823847
cord_uid: jps0wjls

nan

The current wave of COVID-19 infections, which widely believed as an outbreak that initially sprout within the city of Wuhan in China, is beginning to assume alarming proportions across the globe, as cautioned by reports from the World Health Organization (WHO). Viral incidence rates that began to spike from the early December 2019 were the resultant cause of an infection that had contracted from a novel coronavirus (CoV) (form. 2019-nCoV). By the mid of April 2020, the global number of positive COVID-19 cases, as determined by the WHO, stood at 1,699,576 and has been climbing dangerously. Until the same period, the total deaths worldwide due to the disease were 102,734, the worst affected being the United States. It is worthwhile to note that the typically decorated Coronaviridae family, which pri- However, from a pharmacological viewpoint, we have enough evidence now to believe that the aerosolized droplet transmission of COVID-19 viral particles to the lungs involves several key pathological molecular mechanisms.

It is well-observed among most viruses that, the common mechanism of their entry into a host cell is through receptor-mediated endocytosis. Looking at the bigger picture, we are convinced to think that the receptor employed by the COVID-19 virus to attack and modify the cells in the lungs could most probably be ACE2, a protein that is found on the surface of the cells in the kidney, heart tissues, artery and veins, and most significantly, on the epithelial cells (AT2) of the alveoli of the lungs. Moreover, AT2 cells are vulnerable to virus borne infections (Richardson et al., 2020; Zhao et al., 2020) . Having mentioned that, the COVID-19 viral particles have the notorious tendency to proteolytically generate mutated, biologically active fragments of RAS, namely, Ang II and Ang 1-7. These biological fragments may subsequently activate the AT2 receptors, leading them to bind with ACE2. AT2 is a type of G-protein coupled receptor (Clayton proliferation at a faster rate in the later stages of apoptosis in defective cell (Figure 1 ).

Here, we conclude that the COVID-19 virus activates the JNK and JAK-STAT mediated biochemical mechanisms in lungs, resulting in the proliferation and transmission of viral cells. Moreover, before recommending ACE2 inhibitors, it is worthwhile to be mindful and aware of the complications that arise during the blockade of the enzyme, which could lead to cardiac hypertrophy and fibrosis. Thus, we summarize that both JNK and JAK-STAT pathways could be targeted pharmacologically for the inhibition of the COVID-19 infection. Moreover, there must be effective strategies to contain the spread before a vaccine can be developed.

https://orcid.org/0000-0001-7941-0229

Kamal Dua https://orcid.org/0000-0002-7507-1159

Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2

Chronic activation of JNK JAK/STAT and oxidative stress signalling causes the loser cell status

Effect of angiotensin II type 2 receptor on tyrosine kinase Pyk2 and c-Jun NH2-terminal kinase via SHP-1 tyrosine phosphatase activity: Evidence from vascular-targeted transgenic mice of AT2 receptor

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Effect of combination of renin inhibitor and mas-receptor agonist in DOCA-salt-induced hypertension in rats

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan

Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin